Trimu 5 | 90815-77-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Trimu 5
• 英文别名: (2S)-2-amino-3-(4-hydroxyphenyl)-N-[(2R)-1-[[2-(3-methylbutylamino)acetyl]amino]-1-oxopropan-2-yl]propanamide
• CAS: 90815-77-3
• 化学式: C₁₉H₃₀N₄O₄
• 分子量: 378.5
• InChiKey: QOGVSHVPIMZZRN-CJNGLKHVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  27
• 可旋转键数：
  10
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  134
• 氢给体数：
  5
• 氢受体数：
  6

文献信息

• ABUSE-DETERRENT PHARMACEUTICAL COMPOSITION
  申请人：G.L. Pharma GmbH

  公开号：EP3210596A1

  公开（公告）日：2017-08-30

  Disclosed is an abuse-deterrent pharmaceutical composition comprising a drug with an enzyme-reactive functional group, wherein the drug has an abuse potential, and an enzyme capable of reacting with the enzyme-reactive functional group (a drug-processing enzyme), wherein the drug with the enzyme-reactive functional group is contained in the pharmaceutical composition in a storage stable, enzyme-reactive state and under conditions wherein no enzymatic activity acts on the drug.

  本发明公开了一种抑制滥用的药物组合物，该药物组合物包含具有酶反应官能团的药物（其中该药物具有滥用潜力）和能够与酶反应官能团发生反应的酶（药物加工酶），其中具有酶反应官能团的药物以贮存稳定、酶反应状态包含在药物组合物中，并且在没有酶活性作用于该药物的条件下。
• ABUSE-DETERRENT PHARMACEUTICAL COMPOSITIONS
  申请人：G.L. Pharma GmbH

  公开号：EP3231420A1

  公开（公告）日：2017-10-18

  Disclosed are pharmaceutical compositions comprising a drug with a laccase-reactive functional group and a laccase (EC 1.10.3.2) and methods for manufacturing such compositions.

  所公开的是包含具有漆酶反应性官能团的药物和漆酶（EC 1.10.3.2）的药物组合物，以及制造这种组合物的方法。
• Abuse-deterrent pharmaceutical composition
  申请人：G.L. PHARMA GMBH

  公开号：US11077196B2

  公开（公告）日：2021-08-03

  Disclosed is an abuse-deterrent pharmaceutical composition comprising a drug with an enzyme-reactive functional group, wherein the drug has an abuse potential, and an enzyme capable of reacting with the enzyme-reactive functional group (a drug-processing enzyme), wherein the drug with the enzyme-reactive functional group is contained in the pharmaceutical composition in a storage stable, enzyme-reactive state and under conditions wherein no enzymatic activity acts on the drug.

  本发明公开了一种抑制滥用的药物组合物，该药物组合物包含具有酶反应官能团的药物（其中该药物具有滥用潜力）和能够与酶反应官能团发生反应的酶（药物加工酶），其中具有酶反应官能团的药物以贮存稳定、酶反应状态包含在药物组合物中，并且在没有酶活性作用于该药物的条件下。
• PHARMACEUTICAL COMPOSITIONS
  申请人：LOCL Pharma, Inc.

  公开号：US20150290211A1

  公开（公告）日：2015-10-15

  Provided herein are methods and compositions for effective pain treatment, which also reduce or eliminate adverse effects.
• CXCR4 UP- AND DOWN-REGULATION FOR TREATMENT OF DISEASES OR DISORDERS
  申请人：DREXEL UNIVERSITY

  公开号：US20160271248A1

  公开（公告）日：2016-09-22

  The present invention includes a method of treating or preventing HAND in a subject in need thereof, wherein the method comprises administering to the subject a composition that down-regulates ferritin heavy chain (FHC). The present invention further includes a method of treating or preventing HAND in a subject in need thereof, wherein the method comprises administering to the subject a composition that decreases the concentration, expression level and/or activity of IL-1β. The present invention further includes a method of treating or preventing in a subject in need thereof a disease or condition associated with CXCR4 up-regulation, such as but not limited to cancer, metastasis, liver fibrosis (including HIV-associated liver fibrosis), or HIV infection, wherein the method comprises administering to the subject a composition that up-regulates FHC.